% | $
Quotes you view appear here for quick access.

Merrimack Pharmaceuticals, Inc. Message Board

  • gmns888 gmns888 Oct 30, 2013 9:11 AM Flag

    Here is clip from few months ago

    The culprit for Merrimack's shares falling still seems to be disappointment from its interim review of clinical studies for experimental drug MM-121, which is in development with Sanofi. Merrimack announced last week that primary endpoints probably would not be met for a study of MM-121 in treating ovarian cancer, and another study in treating wild type non-small-cell lung cancer. The company also reported a worse-than-expected net loss in its second-quarter financial update last week.

10.50+0.07(+0.67%)Aug 28 4:00 PMEDT